Seattle, United States
Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company founded in 2003. The company is focused on developing next-generation vaccines and immunotherapies using a patented advanced generation adenovirus delivery platform and a validated manufacturing human cell line, collectively known as the Etubics Platform.
The key products developed by Etubics Corporation aim to overcome significant limitations associated with existing adenovirus-based products, including ineffectiveness in the presence of pre-existing immunity, inability to immunize multiple times against the same disease, and inability to immunize against multiple diseases in the same person.
The benefits of Etubics Platform products include being safe and thoroughly studied, effective in the presence of pre-existing immunity, generating a cell-mediated immune response, enabling rapid development, and offering diverse product opportunities.
The company has completed Phase I/IIa clinical trials with its lead product, ETBX-011, an immunotherapeutic designed to treat colorectal cancer. The clinical data for ETBX-011 has been very encouraging, with no reported safety issues or serious adverse effects in both animal and human studies.
The company received its last investment of $4.40M in a Venture Round in April 30, 2014, with the National Institutes of Health as the investor.
With its innovative approach and promising clinical data, Etubics Corporation stands as a potential player in the biotechnology and healthcare industries, positioning itself to make a significant impact in the field of vaccines and immunotherapies.
